Advance Immunology 2018
The EuroSciCon will be holding its CE and CPD accredited for the Advance Immunology 2018 focus on Immunology and Evolution of Infectious Diseases from May 10-12, 2018 in Frankfurt, Germany. The theme of this year’s meeting is “Finding cures for deadly diseases" which will provide an international platform for discussion of present and future challenges in various Sexually transmitted diseases, STDs education, continuing education and expertise meeting. World-leading health practitioners, clinicians, educators and researchers will present cutting-edge and practical clinical techniques based upon widely accepted evidence and will introduce new and emerging research.
Advance Immunology 2018 is the perfect platform for the interaction among specialists, directors, professors, medical, surgical, miscellaneous faculties, experts, and research fellows around the world reputed research institutes, universities and medical schools and mainly accelerating the scientific discoveries in the field of Immunology and Infectious Diseases
Frankfurt is the largest city in the German state of Hesse and the fifth-largest city in Germany. Frankfurt is home to many cultural and educational institutions, including the Goethe University and Frankfurt University of Applied Sciences, many museums and two major botanical gardens: the Palmengarten and the Botanical Garden of Goethe University. Frankfurt is a global hub for commerce, culture, education, tourism and traffic. It is the most important financial centre on the European mainland, with the HQs of the European Central Bank, German Federal Bank, Frankfurt Stock Exchange, Deutsche Bank, Commerzbank, DZ Bank, several fintech start-ups and other institutes. Messe Frankfurt is one of the world's largest trade fairs. Major fairs include the Frankfurt Motor Show, the world's largest motor show, and the Frankfurt Book Fair, the world's largest book fair. Frankfurt has many high-rise buildings in the city centre, forming the Frankfurt skyline. It is one of the few cities in the European Union to have such a skyline and because of it Germans sometimes refer to Frankfurt as Mainhattan, a portmanteau of the local Main River and Manhattan.
Global Immunology Market to Reach $74.2 Billion By 2022
The complexity of the immune system has led to some intrinsic obstacles with clinical research, particularly in relation to targeting the right genes, identifying the appropriate patient population and accessing internal tissues for testing. Market access presents a significant hurdle for immunotherapeutic procedures, as many are high cost and do not deliver the measurements required for traditional cost-effectiveness assessments. Despite these restraining factors, The Global Immunology Market is expected to experience continued growth, from $61.5 Billion in 2015 to $74.2 Billion in 2022, at 2.71% CAGR.
Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5–7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiological linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a highly genericized class of systemic small-molecule-based agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorter-term glucocorticoid therapy, another class of highly genericized systemic agents.
However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal Antibodies (mAbs), which are highly commercially successful due to their widespread usage and high cost. Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth.
Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $61.5 billion in 2015 to $74.2 billion in 2022, at a compound annual growth rate of 2.71%.
- What factors are driving the market growth?
- How can the factors limiting growth are overcome?
- There is a very large pharmaceutical pipeline for immunology, consisting of 1,838 products in active development. However, the commercial performance of the products in the late-stage pipeline is expected to be moderate.
- What gaps in the market are being addressed by the most promising of these late-stage pipeline products?
- How does the composition of the pipeline compare with that of the existing market?
- Several key commercially successful products, including Humira (adalimumab) and Remicade, are due to lose patent protection in the forecast period.
- How will this affect their revenues in this period?
- How are their manufacturers, AbbVie and Johnson & Johnson, responding to this?
- The key players in the market, all of which are among the top 20 pharmaceutical companies, are expected to maintain their market lead throughout the forecast period.
- What is driving this continued market dominance?
- Who will the new market players be?
Reasons to buy:
This report will allow you to
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis
- Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
- Analyze the immunology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
- Understand the growth in patient epidemiology and market revenues for the immunology market globally and across the key players and product types
- Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological disorders
- Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals